Based on a published report [8] and our previous data [9,10,11], we believed that pemafibrate therapy may be effective for NAFLD patients refractory to SGLT2 inhibitors because these two agents have different mechanisms to improve serum ALT levels. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.